HomeCompareHLBBF vs BTI

HLBBF vs BTI: Dividend Comparison 2026

HLBBF yields 2.10% · BTI yields 5.38%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BTI wins by $17.7K in total portfolio value
10 years
HLBBF
HLBBF
● Live price
2.10%
Share price
$6.18
Annual div
$0.13
5Y div CAGR
-50%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.0K
Annual income
$0.21
Full HLBBF calculator →
BTI
BTI
● Live price
5.38%
Share price
$58.47
Annual div
$3.15
5Y div CAGR
11.3%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$37.7K
Annual income
$2,786.64
Full BTI calculator →

Portfolio growth — HLBBF vs BTI

📍 BTI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodHLBBFBTI
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, HLBBF + BTI cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
HLBBF pays
BTI pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

HLBBF
Annual income on $10K today (after 15% tax)
$178.66/yr
After 10yr DRIP, annual income (after tax)
$0.18/yr
BTI
Annual income on $10K today (after 15% tax)
$457.40/yr
After 10yr DRIP, annual income (after tax)
$2,368.64/yr
At 15% tax rate, BTI beats the other by $2,368.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of HLBBF + BTI for your $10,000?

HLBBF: 50%BTI: 50%
100% BTI50/50100% HLBBF
Portfolio after 10yr
$28.9K
Annual income
$1,393.42/yr
Blended yield
4.83%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BTI right now

HLBBF
No analyst data
Altman Z
2.1
Piotroski
5/9
BTI
Analyst Ratings
12
Buy
4
Hold
2
Sell
Consensus: Buy
Price Target
$40.00
-31.6% upside vs current
Range: $40.00 — $40.00
Altman Z
2.1
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

HLBBF buys
0
BTI buys
0
No recent congressional trades found for HLBBF or BTI in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricHLBBFBTI
Forward yield2.10%5.38%
Annual dividend / share$0.13$3.15
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR-50%11.3%
Portfolio after 10y$20.0K$37.7K
Annual income after 10y$0.21$2,786.64
Total dividends collected$211.00$14.3K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples

Year-by-year: HLBBF vs BTI ($10,000, DRIP)

YearHLBBF PortfolioHLBBF Income/yrBTI PortfolioBTI Income/yrGap
1← crossover$10,805$105.09$11,299$598.92$494.00BTI
2$11,615$53.06$12,794$703.91$1.2KBTI
3$12,454$26.65$14,518$829.07$2.1KBTI
4$13,339$13.36$16,513$978.64$3.2KBTI
5$14,280$6.68$18,827$1,157.84$4.5KBTI
6$15,283$3.34$21,518$1,373.12$6.2KBTI
7$16,354$1.67$24,657$1,632.46$8.3KBTI
8$17,500$0.84$28,329$1,945.74$10.8KBTI
9$18,725$0.42$32,637$2,325.33$13.9KBTI
10$20,036$0.21$37,708$2,786.64$17.7KBTI

HLBBF vs BTI: Complete Analysis 2026

HLBBFStock

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, North America, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia. It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership agreement with Verantos to focus on a study to enable real-world evidence in support of migraine therapy; and collaboration with Rgenta Therapeutics, Inc. The company was founded in 1915 and is headquartered in Valby, Denmark.

Full HLBBF Calculator →

BTIConsumer Staples

British American Tobacco p.l.c. provides tobacco and nicotine products to consumers in the Americas, Europe, the Asia-Pacific, the Middle East, Africa, and the United States. It offers vapour, heated, and modern oral nicotine products; combustible cigarettes; and traditional oral products, such as snus and moist snuff. The company provides its products under the Vuse, glo, Velo, Grizzly, Kodiak, Dunhill, Kent, Lucky Strike, Pall Mall, Rothmans, Newport, Natural American Spirit, and Camel brands. The company distributes its products to retail outlets. British American Tobacco p.l.c. was founded in 1902 and is based in London, the United Kingdom.

Full BTI Calculator →
📬

Get this HLBBF vs BTI comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

HLBBF vs SCHDHLBBF vs JEPIHLBBF vs OHLBBF vs KOHLBBF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.